Market revenue in 2022 | USD 344.5 million |
Market revenue in 2030 | USD 2,400.4 million |
Growth rate | 27.5% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 61.1% in 2022. Horizon Databook has segmented the Canada cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Canada has made a medical breakthrough in advanced therapy products. Glybera, the world's first approved gene therapy, was developed in Canada. However, the drug was taken back from the market and is being reviewed by the National Research Council of Canada.
With growing demand for cell and gene therapy products, the need for cell & gene therapy manufacturing in Canada, to accelerate implementation of innovative treatment concepts into standard clinical practices by operating under a common seal of quality, is also increasing.
CellCAN is a Canadian network for regenerative medicine and cell therapy, which focuses on improving the quality, safety, and feasibility of gene & cell therapies in Canada by optimizing manufacturing processes.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Canada cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account